Simplifying Complexity

Specificity
at scale.^™

Sapient accelerates your discovery program through large scale identification of biomarkers.

A drug candidate with an associated biomarker is 2-10x more likely¹ to obtain FDA approval. To date, however, the discovery of circulating biomarkers has been limited.

Sapient’s technology-based approaches break free from the limitations of traditional methods, enabling large scale measurement of thousands of circulating molecules to rapidly identify key biomarkers that inform drug development – including diagnostic biomarkers, pharmacodynamic biomarkers, drug efficacy biomarkers, and more.

EXPLORE THE APPLICATIONS

One platform — a wealth of actionable insights delivered.

Target Identification

Identify the best molecular biomarkers or new target candidates with activity that can be modulated by a therapeutic.
Early Disease Detection

Identify individuals at high risk for disease, years before onset, to develop drugs that more effectively limit disease progression.
Disease Progression

Reveal unique pathways essential to progressive disease and sub-stratify patients according to rapid progressors.
Assessment of Target Engagement

Confirm pharmacological engagement of key targets.
Patient Stratification / Companion Diagnostics

Identify patients most likely to benefit from a specific therapeutic intervention, and develop CLIA-certified diagnostic assays as a companion to therapies.
Safety Profiling

Predict adverse drug responses to obtain a more accurate view of potential drug safety issues, earlier in development.
Pharmacometrics and QSP

Uncover specific biomarkers for dosing and timing to maximize efficiency of drug therapies.
Clinical Trial Optimization

Reduce the size and accelerate the speed of trials by identifying patients most likely to respond positively to the drug.
Chemical Signatures of Disease

Identify new drug targets by uncovering biological drivers of disease.
Reagent Validation

Obtain accurate and rapid measurement of drug composition and purity.